Results 81 to 90 of about 20,923 (159)

Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. [PDF]

J Clin Invest
Taylor SI.
europepmc   +1 more source

Empagliflozin Targets NF-κB Signaling Through PTGS2 and TLR4 in Polycystic Ovary Syndrome: A Drug Repurposing Study and Molecular Simulation. [PDF]

J Xenobiot
Nugraha IC, Febriza A, Tajuddin A, As'ad S.   +3 more
europepmc   +1 more source

Assessing clinical relevance of off-target effects observed at suprapharmacological concentrations of SGLT2 inhibitors. Reply. [PDF]

J Clin Invest
Abdualkader AM, Al Batran R.
europepmc   +1 more source

Two concurrent mechanisms are responsible for the INa increase produced by dapagliflozin and empagliflozin in healthy and heart failure cardiomyocytes

Dapagliflozin and empagliflozin exert many cardiovascular protective actions in heart failure (HF) patients. HF-induced electrical remodelling decreases the expression of Nav1.5 channels (encoded by SCN5A) that generate the cardiac Na+ current (INa ...
Pérez Martín, Sara, Rapún, Josu, Cámara Checa, Anabel, Delpón Mosquera, María Eva, López, Begoña, San José, Gorka, González, Arantxa, Martínez Blanco, Elena, Gómez García, Ricardo, Rubio Alarcón, Marcos, Tamargo Menéndez, Juan, Núñez Fernández, Roberto, Hoban, Adam, Crespo García, María Teresa, Caballero Collado, Ricardo, Díez Guerra, F. Javier   +15 more
core   +1 more source

Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. [PDF]

J Diabetes
Ke W, Kong Y, Fu S, Wang L, Pan Y, Zhong S, Jiang Y, Chen H, Jiao X, Sha F, Xu L, Shao W, Lan F, Chen X, Yan B, Zhou G, Shi P, Li F, He H, Li H, Zhang G, Duan H, Wang F, Gong W, Bai Y, Wang B, Mou X, He L, Ma W, Song J, Zheng J, Bai X, Li X, Yan X, Wang Y, Wang Z, Yuan J, Lu W, Liang Y, Wang Y, Xu F, Li X, Lin X, Zhu H, Xu L, Lou X, Wang L, Cui L, Wang L, Qian H, Shi Y, Li Y.   +51 more
europepmc   +1 more source

Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. [PDF]

BMJ Open
Aladul MI, Hijazeen RA, Al-Shammaa ZM.
europepmc   +1 more source

Effect of empagliflozin with or without carvedilol on tricuspid regurgitation and right ventricular remodeling: PROVE trial. [PDF]

J Cardiovasc Imaging
Kim GY, Lim SM, Yang DH, Lee JE, Lee S, Park SJ, Hwang IC, Yoon YE, Shim CY, Kim HK, Yun SC, Song JM, Kang DH.   +12 more
europepmc   +1 more source

Realizing Benefits of First-in-Class Generic Entry-The Case of SGLT2 Inhibitors. [PDF]

Clin Pharmacol Ther
Gondi S, Kesselheim AS, Rome BN.
europepmc   +1 more source

SGLT2 Inhibitor Empagliflozin Reduces Circulating Monocyte-Platelet Aggregates: A Pilot Study. [PDF]

Circulation
Safa BI, Oakes JM, Simmons JD, Nian H, Kirk LA, Cassidy AC, Olson EC, Hatem Z, Warren CM, Gonzalez MS, Amin T, Sheng Q, Matta A, Zhu L, Hairan W, Howard SE, Flynn CR, Stier MT, Wilfong EM, Rathmell JC, Cahill KN, Brown JD, Beckman JA, Gabriel CL, Freedman JE, Luther JM, Bailin SS, Wanjalla CN, Koethe JR, Kalams SA, Mashayekhi M.   +30 more
europepmc   +1 more source

Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway. [PDF]

Front Endocrinol (Lausanne)
Zhang X, Mao Y, Wu J, Deng X, Wang H, Kang Z.   +5 more
europepmc   +1 more source